Key result
Statin therapy shows conflicting effects in intracerebral hemorrhage, with potential risks alongside post-event benefits.
Why the study?
There is discordance in findings and a lack of well-designed prospective clinical trials regarding the risks and benefits of statin therapy in patients with or at risk for intracerebral hemorrhage.
Does statin therapy improve clinical outcomes or increase the risk of intracerebral hemorrhage in patients with or at risk for ICH?
Does statin therapy improve clinical outcomes or increase the risk of intracerebral hemorrhage in patients with or at risk for ICH?
The use of statins in patients with or at risk for intracerebral hemorrhage remains complex due to conflicting evidence regarding risks and benefits, highlighting the need for prospective clinical trials.
Statin decisions in ICH remain uncertain; discordant Level 4 evidence leaves optimal strategy unresolved pending RCTs.
Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.
No takes yet. Share an insight, caveat, or question.
Kiser et al. (2016) conducted a review in Intracerebral hemorrhage (ICH). Statin therapy was evaluated. Statin therapy in patients with intracerebral hemorrhage has discordant evidence, with potential risks for incident hemorrhage but possible benefits when continued or initiated post-hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: